2-[3-[2-(4,5-Dimethyl-1,3-thiazol-2-yl)-3-(4-sulfophenyl)tetrazol-2-ium-5-yl]phenoxy]acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[3-[2-(4,5-Dimethyl-1,3-thiazol-2-yl)-3-(4-sulfophenyl)tetrazol-2-ium-5-yl]phenoxy]acetic acid
• 化学式: C20H18N5O6S2+
• 分子量: 488.5
• InChiKey: APRZHQXAAWPYHS-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  185
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Compositions and Methods for Treating Proliferation Disorders
  申请人：Arqule, Inc.

  公开号：US20160067260A1

  公开（公告）日：2016-03-10

  The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine).

  本发明涉及利用3-(3-(4-(1-氨基环丁基)苯基)-5-苯基-3H-咪唑并[4,5-b]吡啶-2-基)吡啶-2-胺或3-(3-(4-(1-氨基环丁基)苯基)-5-(3-吗啉基苯基)-3H-咪唑并[4,5-b]吡啶-2-基)吡啶-2-胺或N-(1-(3-(3-(4-(1-氨基环丁基)苯基)-2-(2-氨基吡啶-3-基)-3H-咪唑并[4,5-b]吡啶-5-基)苯基)哌啶-4-基)-N-甲基乙酰胺等化合物治疗细胞增殖性疾病，如癌症或普罗特斯综合征的方法。本发明的方法还可以涉及利用上述化合物与((R)-6-(2-氟苯基)-N-(3-(2-((2-甲氧基乙基)氨基)乙基)苯基)-5,6-二氢苯并[h]喹唑啉-2-胺)结合治疗细胞增殖性疾病，如癌症或普罗特斯综合征的方法。
• ISOXAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Tzeng Cherng-Chyi

  公开号：US20090215768A1

  公开（公告）日：2009-08-27

  An isoxazole derivative is provided. The isoxazole derivative has following formula: wherein R 1 , R 2 , R 3 , R 4 and R 5 , independently, include hydrogen, hydroxy or C 1 -C 12 alkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis and cancer including an isoxazole derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

  提供了一种异噁唑衍生物。该异噁唑衍生物具有以下化学式：其中R1、R2、R3、R4和R5独立地包括氢、羟基或氧化环氧烷、硫环氧烷、氮杂环丙胺、氨基、环氨基、氨基羟基或环氨基羟基的C1-C12烷氧基。该发明还提供了一种治疗骨质疏松症和癌症的药物组合物，包括一种异噁唑衍生物或其药学上可接受的盐以及一种药学上可接受的载体。
• Peptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
  申请人：Arbor Vita Corporation

  公开号：EP2385124A2

  公开（公告）日：2011-11-09

  The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.

  本发明提供的试剂和方法可抑制或增强造血细胞和其他参与免疫反应调解的细胞中蛋白质之间的相互作用。 所提供的试剂和方法可用于治疗由免疫系统细胞介导的各种疾病和病症。
• Clasp-4 transmembrane protein
  申请人：——

  公开号：US20020068302A1

  公开（公告）日：2002-06-06

  The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-4 (“CLASP-4”). In particular, it relates to CLASP-4 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-4 function.

  本发明涉及一种细胞表面分子，名为 "类固着蛋白不对称蛋白-4"（CLASP-4）。本发明尤其涉及 CLASP-4 多核苷酸、多肽、融合蛋白和抗体。本发明还涉及通过干扰 CLASP-4 功能来调节免疫反应的方法。
• Clasp-3 transmembrane protein
  申请人：——

  公开号：US20020086382A1

  公开（公告）日：2002-07-04

  The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-3 (“CLASP-3”). In particular, it relates to CLASP-3 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-3 function.

  本发明涉及一种细胞表面分子，名为 "类固着蛋白不对称蛋白-3"（CLASP-3）。本发明尤其涉及 CLASP-3 多核苷酸、多肽、融合蛋白和抗体。本发明还涉及通过干扰 CLASP-3 功能来调节免疫反应的方法。